Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

NCT06427798 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

66

Enrollment

NIH

Sponsor class

Conditions

Somatostatin Receptor Positive
Gastrointestinal Neuroendocrine Tumors
Pheochromocytoma
Paragangliomas

Interventions

DRUG: 68Ga-DOTATATE
DRUG: [203Pb]VMT-alpha-NET
DRUG: [212Pb]VMT-alpha-NET

Sponsor

National Cancer Institute (NCI)